[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,098,289
  • Shares Outstanding, K 155,565
  • Annual Sales, $ 418,840 K
  • Annual Income, $ -1,600 K
  • EBIT $ 66 M
  • EBITDA $ 142 M
  • 60-Month Beta 1.46
  • Price/Sales 2.48
  • Price/Cash Flow 8.81
  • Price/Book 1.01

Options Overview Details

View History
  • Implied Volatility 171.79% (+9.65%)
  • Historical Volatility 71.74%
  • IV Percentile 45%
  • IV Rank 22.92%
  • IV High 555.01% on 02/12/26
  • IV Low 57.81% on 01/16/26
  • Expected Move (DTE 1) 0.17 (2.32%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 33
  • Volume Avg (30-Day) 256
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 5,105
  • Open Int (30-Day) 2,631
  • Expected Range 7.15 to 7.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.06
  • Number of Estimates 3
  • High Estimate $0.07
  • Low Estimate $0.05
  • Prior Year $0.03
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.30 +38.27%
on 06/22/26
7.39 -0.74%
on 07/07/26
+1.28 (+21.24%)
since 06/16/26
3-Month
4.45 +64.83%
on 05/15/26
7.39 -0.74%
on 07/07/26
+1.18 (+19.07%)
since 04/16/26
52-Week
4.45 +64.83%
on 05/15/26
13.88 -47.15%
on 10/03/25
-3.07 (-29.54%)
since 07/16/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT).  Such investors are advised to...

CERT : 7.37 (+4.39%)
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second...

CERT : 7.37 (+4.39%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT).  Such investors are advised to...

CERT : 7.37 (+4.39%)
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform,...

CERT : 7.37 (+4.39%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact...

CERT : 7.37 (+4.39%)
Certara Announces CFO Transition

RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the...

CERT : 7.37 (+4.39%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT).  Such investors are advised to...

CERT : 7.37 (+4.39%)
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 8, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara,...

CERT : 7.37 (+4.39%)
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference

Certara (NASDAQ:CERT) executives outlined the company’s strategic realignment, artificial intelligence initiatives and cost priorities during a discussion at Jefferies’ 2026 Global Healthcare Conference,...

CERT : 7.37 (+4.39%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact...

CERT : 7.37 (+4.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Certara Inc. provides medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Certara Inc. is based in NJ, United States.

See More

Key Turning Points

3rd Resistance Point 7.53
2nd Resistance Point 7.31
1st Resistance Point 7.18
Last Price 7.37
1st Support Level 6.84
2nd Support Level 6.62
3rd Support Level 6.49

See More

52-Week High 13.88
Fibonacci 61.8% 10.28
Fibonacci 50% 9.16
Fibonacci 38.2% 8.05
Last Price 7.37
52-Week Low 4.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.